Barclays PLC Boosts Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Barclays PLC grew its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 101,257 shares of the company's stock after buying an additional 10,737 shares during the period. Barclays PLC owned 0.13% of CG Oncology worth $2,905,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in CG Oncology during the 4th quarter valued at $68,000. KLP Kapitalforvaltning AS purchased a new position in shares of CG Oncology during the fourth quarter valued at about $100,000. Federated Hermes Inc. bought a new position in CG Oncology in the fourth quarter worth about $172,000. Meeder Asset Management Inc. purchased a new stake in CG Oncology in the fourth quarter worth about $189,000. Finally, NEOS Investment Management LLC boosted its position in CG Oncology by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock valued at $239,000 after acquiring an additional 817 shares in the last quarter. Institutional investors own 26.56% of the company's stock.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $30.76, for a total value of $30,760.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Analyst Upgrades and Downgrades

CGON has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a research report on Monday, April 28th. JPMorgan Chase & Co. initiated coverage on CG Oncology in a report on Friday. They issued an "overweight" rating and a $41.00 price objective for the company. Morgan Stanley restated an "overweight" rating and set a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research note on Monday, April 28th. Finally, TD Cowen started coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, CG Oncology presently has a consensus rating of "Buy" and a consensus price target of $57.70.

CG Oncology Stock Up 4.7 %

CGON traded up $1.31 during midday trading on Friday, hitting $29.05. 1,160,711 shares of the company traded hands, compared to its average volume of 781,739. The company's 50-day moving average is $23.68 and its 200 day moving average is $28.96. The firm has a market capitalization of $2.21 billion, a PE ratio of -20.46 and a beta of 1.24. CG Oncology, Inc. has a 52 week low of $14.80 and a 52 week high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. On average, sell-side analysts predict that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.